Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

March 19, 2021 by Alan Khadavi

Xolair for Idiopathic Anaphylaxis

Xolair for idiopathic anaphylaxis was recently studied in a randomized double-blind, placebo-controlled study. We have discussed idiopathic anaphylaxis in the past in a blog post.

It is a diagnosis of exclusion, so there is no inciting agent. Epinephrine followed by systemic steroids are the mainstays of therapy for acute events. There is no prophylactic therapy that reliably prevents anaphylaxis.

Anaphylaxis is a systemic reaction associated with the release of mediators from mast cells and basophils. Signs and symptoms are flushing, hives, congestion, eye irritation, bronchospasm, swelling of the tongue, throat, palms and soles, GI cramping, light headedness and loss of conciousness.

Common causes are allergic reactions to foods, drugs or stinging insects. A factor is identified in up to 50% of the patients with recurrent episodes. Idiopathic anaphylaxis is categorized as frequent (2 episodes in past 2 months or greater than 6 episodes in past year) or infrequent (less than 6 episodes a year).

Management consists of epinephrine, airway protection and support of circulation.

Xolair (omalizumab) is approved for the treatment of moderate to severe asthma and chronic urticaria. (More recently nasal polyps). Xolair targets IgE and several reports showed it worked for idiopathic anaphylaxis, systemic mastocytosis or mast cell activation syndrome.

A recent study completed 16 patients in a trial of Xolair for idiopathic anaphylaxis. No statistically significant difference was demonstrated between the placebo and treated groups. There was a trend for efficacy in the treatment group, but it wasn’t significant.

The key messages from this study are:

  • Xolair for idiopathic anaphylaxis cannot be expected to prevent subsequent episodes of anaphylaxis, and if it administered, careful monitoring is required to evaluate success.
  • Because idiopathic anaphylaxis can decrease in severity and frequency, with time, any intervention must be evaluated on a case by case basis for efficacy.

Although there are several case reports in the literature that relate efficacy of Xolair for idiopathic anaphylaxis, these studies only enrolled 1 case.

Idiopathic Anaphylaxis-Workup and Treatment

 

Filed Under: Anaphylaxis, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

January 22, 2023

Is Benadryl Safe to use, or is it Time to Move on?

is benadryl safe

January 12, 2023

Airsupra for Asthma, a new rescue medication

airsupra

December 26, 2022

Cantaloupe Allergy comes in many flavors

cantaloupe allergy

December 23, 2022

Remibrutinib, a BTK inhibitor for Chronic Hives

remibrutininb

November 21, 2022

Eczema and Hard Water, is there a link?

eczema and hard water

November 19, 2022

Nucala, Fasenra or Dupixent for Severe Eosinophilic Asthma?

nucala fasenra dupixent

November 18, 2022

Xolair for idiopathic angioedema

xolair for idiopathic angioedema

September 29, 2022

When will my child outgrow egg allergy?

outgrow egg allergy

September 13, 2022

Can you be allergic to water? (Aquagenic Urticaria)

allergic to water

September 8, 2022

Oclacitinib for Atopic Dermatitis (Eczema) in Dogs

oclacitinib

Read More Posts...

Follow Us…

© 2023 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page